Stifel maintains its 'hold' rating on Roche shares, with a price target reduced from 306 to 280 Swiss francs.

The broker reports that despite an expected increase in operating profit in 2024, investors remain concerned about earnings per share, which are expected to be lower than in 2018, notably due to an estimated 500 million Swiss francs increase in financial expenses and 800 million Swiss francs in taxes.

Stifel reports that Roche will hold various investor relations events, including the traditional Pharma Day in September, during which an update on the group's strategy is planned.

' Needless to say, we expect the event to be well attended, but we also point out that performing ahead of this event could prove challenging,' the analyst stresses.

Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.